Hot Lines & Clinical Trial Updates
Hot lines are sessions reserved for first presentations of the primary endpoint(s) of recently completed clinical trials while Clinical Trial Updates are sessions for new data or analyses of trials recently presented at previous meetings.
Hot Line I - Cardiovascular risk and complications
Sunday 28 August 11:00-12:30 Room: Paris - Zone F
Chairpersons: M Bohm (Homburg/Saar, DE), M Komajda (Paris, FR)
PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 people - S Yusuf (Hamilton, CA)
Discussant - A P Maggioni (Florence, IT)
HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease U Laufs (Homburg, DE)
Discussant - P J Barter (Sydney, AU)
dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease - T F Luescher (Zurich, CH)
Discussant - K A A Fox (Edinburgh, GB)
ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trial C B Granger (Durham, US)
Discussant - M D Ezekowitz (Villanova, US)
CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trial - M Imazio (Torino, IT)
Discussant - A Keren (Jerusalem, IL)
Clinical Trial Update I - Drug treatment
Sunday 28 August 2011 - 14:00-15:30 - Room: Paris - Zone F
Chairpersons: S Agewall (Oslo, NO), G Parcharidis (Thessaloniki, GR)
KYOTO HEART Study: Cardiovascular protective effects of valsartan in high-risk hypertensive patients with chronic kidney disease: updated analysis of KYOTO HEART Study T Sawada (Kyoto, JP)
Discussant - J Redon (Valencia, ES)
ASCOT: Anglo-Scandinavian Cardiac Outcomes Trial: 10 year follow-up of the Lipid_lowering Arml P S Sever (London, GB)
Discussant - G De Backer (St Martens Latem, BE)
ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial - L C Wallentin (Uppsala, SE)
Discussant - J-P Collet (Paris, FR)
ROCKET AF: Prevention of stroke and systemic embolism using the oral direct factor Xa inhibitor Rivaroxaban compared with Warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment
K A A Fox (Edinburgh, GB)
Discussant - S H Hohnloser (Frankfurt, DE)
RE-LY: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY®) trial
AM Dans (Manila, PH)
Discussant - FWA Verheugt (Amsterdam, NL)
ONTARGET: Medication adherence and outcomes in high-risk cardiovascular patients in the ONTARGET trial M Bohm (Homburg/Saar, DE)
Discussant - L Tavazzi (Cotignola, IT)
Hot Line II - Frontiers in interventional and device treatments
Monday 29 Aug 2011 - 11:00-12:30 Room: Paris - Zone F
Chairpersons: S Goldstein (Detroit, US), F J Pinto (Lisbon, PT)
EVATEL: Remote follow-up of patients implanted with an ICD: the prospective randomized EVATEL study. P Mabo (Rennes, FR)
Discussant - A Auricchio (Lugano, CH)
ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial S Kacet (Lille, FR)
Discussant - J C Daubert (Rennes, FR)
EMPHASIS-HF: The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study population B Pitt (Ann Arbor, US)
Discussant - P Ponikowski (Wroclaw, PL)
RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial T Kimura (Kyoto, JP)
Discussant - S Windecker (Berne, CH)
Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2 H Shiomi (Kyoto, JP)
Discussant - F Van de Werf (Leuven, BE)
Clinical Trial Update II - Rate and rhythm
Monday 29 August 2011 - 14:00-15:30 - Room: Paris - Zone F
Chairpersons: G S Filippatos (Athens, GR), K-H Kuck (Hamburg, DE)
SMART-AV: The role of electrical delay (QLV) to predict left ventricular reverse remodeling with cardiac resynchronization therapy M R Gold (Charleston, US)
Discussant - C Linde (Stockholm, SE)
PACE: Biventricular pacing superior to right ventricular pacing in bradycardia patients with preserved systolic function: two-year results of PACE trial
CM Yu (Hong Kong, HK)
Discussant - K Dickstein (Stavanger, NO)
IRIS: Why does the implantable cardioverter-defibrillator not improve mortality early after myocardial infarction - Insights from the Immediate Risk Stratification Improves Survival (IRIS) trial G Steinbeck (Munich, DE)
Discussant - C Leclercq (Rennes, FR)
SHIFT: Relationship between heart rate and health related quality of life. Results from SHIFT - I Ekman (Goteborg, SE)
Discussant - E Erdmann (Koeln, DE)
SHIFT: Selective heart rate reduction with Ivabradine improves left ventricular remodeling and function: insights from the SHIFT-Echocardiography sub-study
J-C Tardif (Montreal, CA)
Discussant - B M Pieske (Graz, AT)
STICH: Influence of mitral valve repair on survival in the surgical treatment for Ischemic heart failure trial M Deja (Katowice, PL)
Discussant - A Vahanian (Paris, FR)
Hot Line III - Acute coronary syndromes
30 Aug 2011 - 11:00-12:30 - Room: Paris - Zone F
Chairperson: R Ferrari (Ferrara, IT), C Stefanadis (Paleo Psychico, GR)
PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention.
M Valgimigli (Ferrara, IT)
Discussant - A Kastrati (Munchen, DE)
The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome P G Steg (Paris, FR)
Discussant - S D Kristensen (Aarhus N, DK)
EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction M Sabate Tenas (Barcelona, ES)
Discussant - W Wijns (Aalst, BE)
Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents L Raber (Berne, CH)
Discussant - J Fajadet (Toulouse, FR)
CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial
M Patel (Durham, US)
Discussant - K Huber (Vienna, AT)
Access reports on Hot lines and Clinical Trial Updates presented during ESC Congress 2010 in Stockholm.
Back to types of sessions
Meet the Trialists
These sessions will cover the best of the Hot Line sessions and will provide the opportunity to interact directly with the Presenters of the featured trials. The sessions will take place after the Hot Line presentations - hot off the press!
Click here to discover the sessions 
(268 Kb)
Back to types of sessions
NEW Clinical Registry Highlights
Clinical registry highlights have been introduced to highlight a growing number of excellently performed innovative registries. The primary outcomes of these registries should be presented for the first time in this new session type.
CRH I - Risk and treatment reality - New clinical registry data
Sunday 28 August 2011 - Time: 16:30-18:00 - Room: Paris - Zone F
Chairpersons: L Tavazzi (Cotignola, IT), F J Pinto (Lisbon, PT)
EUROACTION preventive cardiology programme plus intensive smoking cessation with Varenicline D A Wood (London, GB)
EUROASPIRE III: modelling the clinical and cost-effectiveness of optimizing cardiovascular prevention in patients with established coronary heart disease in Europe L Annemans (Gent, BE)
Quality of care at discharge is affected by hospital case volume in acute myocardial infarction patients. A French nationwide assessment
F Schiele (Besancon, FR)
"Atrial fibrillation ablation" European survey: short-term results.
J Brugada Terradellas (Barcelona, ES)
GARFIELD: Multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield Registry A Kakkar (London, GB)
Global variation in the etiology and management of atrial fibrillation: results from a global atrial fibrillation registry J Healey (Hamilton, CA)
CRH II - Interventions and devices - New clinical registry data
Monday 29 August 2011 - 16:30-18:00 - Room: Paris - Zone F
Chairpersons: M Borggrefe (Mannheim, DE), F Van de Werf (Leuven, BE)
The Italian Elderly ACS study: Early aggressive versus initially conservative strategy in elderly patients with non-ST- elevation acute coronary syndrome
S Savonitto (Milano, IT)
Is clopidogrel discontinuation following acute coronary syndrome hospitalisation associated with a higher risk of death and myocardial infarction?
A D Timmis (London, GB)
The PACIFIC registry: one-year follow-up data of a 2-Year study in patients initially hospitalised with ACS K Miyauchi (Tokyo, JP)
DK: Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a nationwide study of 7.4 million individuals
B G Nordestgaard (Copenhagen, DK)
The European CRT survey: 1 year follow-up results N Bogale (Sandnes, NO)
FRANCE II: French registry aortic national corevalve and Edwards registry II
M Gilard (Brest, FR)
Back to types of sessions
Basic & Translational Science Hot Line
This session will present the latest and "hottest" findings of studies in basic and translational cardiovascular science; including cellular, molecular and genetic research and functional studies in genetically engineered mice and larger mammals.
Monday 29 August 2011 - 08:30-10:00 - Room: Tripoli - Zone A
Chairpersons: J L Balligand (Brussels, BE), J Waltenberger (Muenster, DE)
Mitochondrial localization unveils a novel role for GRK2 in the regulation of oxidative metabolism. A Fusco (Napoli, IT)
Antibody-coupling and targeting of microbubbles to activated platelets allows molecular imaging of thrombosis and monitoring of success or failure of thrombolysis using non-invasive ultrasound. K Peter (Melbourne, AU)
Modeling of Familial Dilated Cardiomyopathy Caused by Mutation in Lamin A/C Gene Using Patient-Specific Induced Pluripotent Stem Cells
CW Siu (Hong Kong Sar, HK)
A critical role for STIM1 in cardiac hypertrophy J-S Hulot (Paris, FR)
Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell Formation in Human Atherosclerotic Plaques A Finn (Atlanta, US)
miR-145: A role in the development of pulmonary arterial hypertension
P Caruso (Glasgow, GB)
Back to types of sessions